Meletios A. Dimopoulos, MD, on the Phase III BOSTON Study in Multiple Myeloma

June 8, 2020
Meletios A. Dimopoulos, MD
Meletios A. Dimopoulos, MD

Meletios A. Dimopoulos, MD, discussed the phase III Boston study examining a new combination therapy to treat patients with multiple myeloma who have received 1 to 3 prior therapies.

Meletios A. Dimopoulos, MD, discussed the phase III Boston study presented at the 2020 ASCO Virtual Scientific Program examining a new combination therapy to treat patients with multiple myeloma who have received 1 to 3 prior therapies.

Transcription:

We have a new triplet—selinexor (Xpovio), bortezomib (Velcade), and dexamethasone—which could be administered for patients who have received 1 to 3 prior lines of therapy. It could be 1 of the treatments that could be used for patients who have been exposed and progress on lenalidomide (Revlimid) maintenance or continuous treatment. I believe it is an additional combination for the treatment of myeloma patients.

It gives another combination. For example, whenever we have patients who progressed on lenalidomide, often times we use a pomalidomide-based regimen. In this case, we could change completely the mode of action, move to a combination that is not including anemic, and then maybe use pomalidomide (Pomalyst) later on.